




RealRate

# PHARMACEUTICAL 2021

uniQure N.V.  
Rank 159 of 402

uniQure





# PHARMACEUTICAL 2021

uniQure N.V.  
Rank 159 of 402

uniQure

The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 44% points. The greatest weakness of uniQure N.V. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 91% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	258,911
Cost of Goods Sold	0
Intangible Assets	3,903
Liabilities, Current	27,334
Liabilities, Non-Current	69,156
Other Assets	45,253
Other Compr. Net Income	16,596
Other Expenses	-11,292
Other Liabilities	0
Other Net Income	-12,192
Other Revenues	40,856
Property and Equipment	32,328
Research and Development	122,400
Selling, General and Administrative Expense	42,580

Output Variable	Value in 1000 USD
Assets	340,395
Liabilities	96,490
Expenses	153,688
Revenues	40,856
Stockholders Equity	243,905
Net Income	-125,024
Comprehensive Net Income	-116,726
Economic Capital Ratio	139%